Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (245)

1

Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults : A phase 3, randomized, active-controlled, multicenter trial

enthalten in: Vaccine | 2024

von Nurdin, A. | Movieta Nency, Y. | Maddeppungeng, M. | +24

2

Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand

enthalten in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy | 2024

von Mikamo, H. | Takahashi, S. | Yamagishi, Y. | +17

3

Deucravacitinib in plaque psoriasis : 2-year safety and efficacy results from the phase III POETYK trials

enthalten in: The British journal of dermatology | 2024

von Lebwohl, M. | Warren, R. | Sofen, H. | +12

CommentIn: Br J Dermatol. 2024 Feb 26;:. - PMID 38407434

4

High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults

enthalten in: Influenza and other respiratory viruses | 2024

von Palmu, A. | Pepin, S. | Syrjänen, R. | +7

5

Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia : a randomized phase 3 trial with 5-year outcomes

enthalten in: Journal of cancer research and clinical oncology | 2024

von Tian, J. | Song, Y. | Zhang, G. | +24

6

Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine : a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial

enthalten in: The Lancet. Infectious diseases | 2024

von Oda, Y. | Kumagai, Y. | Kanai, M. | +8

7

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19

enthalten in: The New England journal of medicine | 2024

von Hammond, J. | Fountaine, R. | Yunis, C. | +10

8

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) : 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults

enthalten in: Human vaccines & immunotherapeutics | 2024

von Kulkarni, P. | Padmapriyadarsini, C. | Vekemans, J. | +29

9

In mild to moderate COVID-19, VV116 safely reduced time to sustained clinical symptom resolution

enthalten in: Annals of internal medicine | 2024

von Granwehr, B.

10

Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine

enthalten in: Vaccine | 2024

von Toback, S. | Marchese, A. | Warren, B. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[25]